Magnetic resonance spectroscopy imaging in radiotherapy planning for recurrent gliomaa)
Authors:
- Åse M. BallangrudÅBÅse M. Ballangrud
- Stella LymberisSLStella Lymberis
- Sunitha B. ThakurSunitha B. Thakur
- Sasan KarimiSKSasan Karimi
- Wei HuangWHWei Huang
- Lauren E. AbreyLALauren E. Abrey
- Kathryn BealKBKathryn Beal
- Fabio M. IwamotoFIFabio M. Iwamoto
- Cameron BrennanCBCameron Brennan
- Philip H. GutinPGPhilip H. Gutin
- Jenghwa ChangJCJenghwa Chang
- 9 May 2011
- journal article
- Published by Wiley in Medical Physics
- Vol. 38 (5) , 2724-2730
Abstract
The purpose of this study was to investigate how incorporation of magnetic resonance spectroscopy imaging (MRSI) into radiotherapy planning would increase the target volume for patients with recurrent glioma. After prior standard radiotherapy, 25 patients with recurrent glioma were treated with bevacizumab and concurrent hypofractionated stereotactic radiotherapy (HFSRT), delivering 30 Gy in five fractions. MRSI were acquired for 12 patients. Areas with markedly higher choline levels relative to the levels of total creatine and N-acetylaspartate were identified and referred to as MRSI voxels with elevated metabolite ratios (EMR). Gross tumor volume (GTV) consisted of contrast-enhancing tumor on T1-weighted magnetic resonance images (MRI) and computed tomography. Clinical target volume (CTV) was GTV + 5 mm margin and MRSI voxels with EMR. Overall survival (OS) and 6-month progression free survival (PFS) for these patients were reported in a prior publication [Gutin et al., Int. J. Radiat. Oncol., Biol., Phys. 75(1), 156-163 (2009)], and the outcome was correlated with the GTV and the volume of MRSI voxels with EMR in this study. Seven of the 12 patients had MRSI voxels with EMR. If none of the MRSI voxels with EMR were included, the CTV would range from 9.2 to 73.0 cm3 with a median of 31.0 cm3, whereas if all voxels were included, the CTV would range from 27.4 to 74.4 cm3 with a median of 35.0 cm3. For three of the seven patients, including the voxels with EMR, would have increased the CTV by 14%-23%. For one patient, where the MRSI voxels with EMR did not overlap the GTV, including these voxels would increase the CTV by 198%. No correlation could be found between the OS and PFS and the GTV or the volume of MRSI voxels with EMR. Seven of 12 patients with recurrent glioma had MRSI voxels with EMR. For four of these seven patients, including the MRSI voxels with EMR, significantly increased the CTV. This study does not have statistical power to conclude on the importance of including areas with MRSI-suspect disease into the radiation target volume.Keywords
This publication has 24 references indexed in Scilit:
- Safety and Efficacy of Bevacizumab With Hypofractionated Stereotactic Irradiation for Recurrent Malignant GliomasInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- High-grade glioma before and after treatment with radiation and Avastin: Initial observationsNeuro-Oncology, 2008
- Proton Magnetic Resonance Spectroscopic Imaging in Newly Diagnosed Glioblastoma: Predictive Value for the Site of Postradiotherapy Relapse in a Prospective Longitudinal StudyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Patterns of Recurrence Analysis in Newly Diagnosed Glioblastoma Multiforme After Three-Dimensional Conformal Radiation Therapy With Respect to Pre–Radiation Therapy Magnetic Resonance Spectroscopic FindingsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007
- Use of MR spectroscopy and functional imaging in the treatment planning of gliomasBritish Journal of Radiology, 2007
- Correlation of magnetic resonance spectroscopic and growth characteristics within Grades II and III gliomasJournal of Neurosurgery, 2007
- Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapyBiochemical and Biophysical Research Communications, 2005
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004
- Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presenceJournal of Neurosurgery, 2002
- Topographic anatomy and CT correlations in the untreated glioblastoma multiformeJournal of Neurosurgery, 1988